Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 5/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30767968 | 0.88 | SCN9A (0.39) | KCNA3RORCMTNR1AMTNR1BSCN9A | |
| SCHEMBL25331112 | 0.88 | MTNR1A (0.40) | MTNR1AMTNR1BDRD2 | |
| SCHEMBL27057690 | 0.87 | AR (0.42) | KCNA3RORCMTNR1AMTNR1BSCN9A | |
| SCHEMBL27057844 | 0.86 | MTNR1A (0.40) | RORCMTNR1AMTNR1BDRD2AR | |
| SCHEMBL30576526 | 0.85 | TEAD1 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL25330093 | 0.85 | TEAD1 (0.48) | MTNR1AMTNR1B | |
| SCHEMBL30767976 | 0.84 | RORC (0.38) | RORCMTNR1AMTNR1BSCN9ADRD2 | |
| SCHEMBL27057236 | 0.84 | RORC (0.38) | RORCMTNR1AMTNR1BSCN9ADRD2 | |
| SCHEMBL27057645 | 0.84 | RORC (0.38) | RORCMTNR1AMTNR1BSCN9ADRD2 | |
| SCHEMBL27057233 | 0.83 | RORC (0.38) | KCNA3RORCMTNR1AMTNR1BSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | KCNA3 4412/4885RORC 426/4885MTNR1A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.